Epigenetic therapies in MDS and AML

Advances in Experimental Medicine and Biology

Volumn 754, Issue , 2013, Pages 253-283

  Griffiths, Elizabeth A ^a   Gore, Steven D ^b  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; AZACITIDINE; CYCLOPEPTIDE; CYTARABINE; DAUNORUBICIN; ENTINOSTAT; HEMOGLOBIN; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID DERIVATIVE; IDARUBICIN; MITOXANTRONE; MOCETINOSTAT; PHENYLBUTYRATE; ROMIDEPSIN; SHORT CHAIN FATTY ACID; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BONE MARROW TRANSPLANTATION; BRAIN DISEASE; CANCER REGRESSION; CONTINUOUS INFUSION; DIARRHEA; DISEASE COURSE; DNA DAMAGE; DNA METHYLATION; DOSAGE SCHEDULE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; EPIGENETICS; FATIGUE; GASTROINTESTINAL TOXICITY; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMMUNOMODULATION; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPHIL COUNT; NONHUMAN; OUTPATIENT CARE; PATIENT SELECTION; PRIORITY JOURNAL; QUALITY OF LIFE; THROMBOCYTE COUNT; UNSPECIFIED SIDE EFFECT; VOMITING;

EID: 84869006162     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-9967-2_13     Document Type: Article

References (96)

1. Vardiman JW, Harris NL, Brunning RD (2002) The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 100:2292-2302
2. Greenberg PL (1998) Risk factors and their relationship to prognosis in myelodysplastic syndromes. Leuk Res 22(Suppl 1):S3-S6
3. Menzin J, Lang K, Earle CC, Kerney D, Mallick R (2002) The outcomes and costs of acute myeloid leukemia among the elderly. Arch Intern Med 162:1597-1603 (Pubitemid 34773427)
4. Lowenberg B, Downing JR, Burnett A (1999) Acute myeloid leukemia. N Engl J Med 341:1051-1062 (Pubitemid 29451802)
5. Howlader N, Noone AM, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse SF, Kosary CL, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Chen HS, Feuer EJ, Cronin KA, Edwards BK (2011) SEER Cancer Statistics Review, 1975-2008, National Cancer Institute. Bethesda, MD, based on November 2010 SEER data submission, posted to the SEER web site
6. Kantarjian H, O'brien S, Cortes J, Giles F, Faderl S, Jabbour E, Garcia-Manero G, Wierda W, Pierce S, Shan J, Estey E (2006) Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer 106:1090-1098
7. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A, Schoch R, Gattermann N, Sanz G, List A, Gore SD, Seymour JF, Bennett JM, Byrd J, Backstrom J, Zimmerman L, McKenzie D, Beach C, Silverman LR (2009) International Vidaza High-Risk MDS Survival Study Group: Ef fi cacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, openlabel, phase III study. Lancet Oncol 10:223-232
8. Tilly H, Castaigne S, Bordessoule D, Casassus P, Le Prise PY, Tertian G, Desablens B, Henry- Amar M, Degos L (1990) Low-dose cytarabine versus intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly. J Clin Oncol 8:272-279 (Pubitemid 20056558)
9. Gardin C, Turlure P, Fagot T, Thomas X, Terre C, Contentin N, Raffoux E, de Botton S, Pautas C, Reman O, Bourhis JH, Fenaux P, Castaigne S, Michallet M, Preudhomme C, de Revel T, Bordessoule D, Dombret H (2007) Postremission treatment of elderly patients with acute myeloid leukemia in fi rst complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial. Blood 109:5129-5135 (Pubitemid 46900774)
10. Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J, Klimek V, Slack J, de Castro C, Ravandi F, Helmer R III, Shen L, Nimer SD, Leavitt R, Raza A, Saba H (2006) Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 106:1794-1803
11. Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD, Lowenberg B, Beran M, de Witte TM, Stone RM, Mittelman M, Sanz GF, Wijermans PW, Gore S, Greenberg PL (2000) World Health Organization(WHO) international working group: Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 96:3671-3674
12. Cheson BD, Cassileth PA, Head DR, Schiffer CA, Bennett JM, Bloomfield CD, Brunning R, Gale RP, Grever MR, Keating MJ (1990) Report of the National Cancer Institute-sponsored workshop on de fi nitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 8:813-819 (Pubitemid 20148273)
13. Lubbert M, Suciu S, Baila L, Ruter BH, Platzbecker U, Giagounidis A, Selleslag D, Labar B, Germing U, Salih HR, Beeldens F, Muus P, P fl uger KH, Coens C, Hagemeijer A, Eckart Schaefer H, Ganser A, Aul C, de Witte T, Wijermans PW (2011) Low-dose decitabine versus best supportive care in elderly patients with intermediate- or high-risk myelodysplastic syndrome (MDS) ineligible for intensive chemotherapy: fi nal results of the randomized phase III study of the European Organisation for Research and Treatment of Cancer Leukemia Group and the German MDS Study Group. J Clin Oncol 29:1987-1996
14. Kadia TM, Jabbour E, Kantarjian H (2011) Failure of hypomethylating agent-based therapy in myelodysplastic syndromes. Semin Oncol 38:682-692
15. Yang X, Lay F, Han H, Jones PA (2010) Targeting DNA methylation for epigenetic therapy. Trends Pharmacol Sci 31:536-546
16. Weiss AJ, Stambaugh JE, Mastrangelo MJ, Laucius JF, Bellet RE (1972) Phase I study of 5-azacytidine (NSC-102816). Cancer Chemother Rep 56:413-419
17. Karon M, Sieger L, Leimbrock S, Finklestein JZ, Nesbit ME, Swaney JJ (1973) 5-Azacytidine: a new active agent for the treatment of acute leukemia. Blood 42:359-365
18. McCredie KB, Bodey GP, Burgess MA, Gutterman JU, Rodriguez V, Sullivan MP, Freireich EJ (1973) Treatment of acute leukemia with 5-azacytidine (NSC-102816). Cancer Chemother Rep 57:319-323
19. Constantinides PG, Taylor SM, Jones PA (1978) Phenotypic conversion of cultured mouse embryo cells by aza pyrimidine nucleosides. Dev Biol 66:57-71 (Pubitemid 9029803)
20. Jones PA, Taylor SM (1980) Cellular differentiation, cytidine analogs and DNA methylation. Cell 20:85-93 (Pubitemid 10117303)
21. Jones PA, Taylor SM (1981) Hemimethylated duplex DNAs prepared from 5-azacytidinetreated cells. Nucleic Acids Res 9:2933-2947
22. Quesnel B, Guillerm G, Vereecque R, Wattel E, Preudhomme C, Bauters F, Vanrumbeke M, Fenaux P (1998) Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood 91:2985-2990 (Pubitemid 28227550)
23. Esteller M (2003) Pro fi ling aberrant DNA methylation in hematologic neoplasms: a view from the tip of the iceberg. Clin Immunol 109:80-88 (Pubitemid 37324745)
24. Voso MT, Scardocci A, Guidi F, Zini G, Di Mario A, Pagano L, Hohaus S, Leone G (2004) Aberrant methylation of DAP-kinase in therapy-related acute myeloid leukemia and myelodysplastic syndromes. Blood 103:698-700 (Pubitemid 38140107)
25. Silverman LR, Holland JF, Weinberg RS, Alter BP, Davis RB, Ellison RR, Demakos EP, Cornell CJ Jr (1993) Carey RW, Schiffer C: Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia 7(Suppl 1):21-29 (Pubitemid 23184796)
26. Chitambar CR, Libnoch JA, Matthaeus WG, Ash RC, Ritch PS, Anderson T (1991) Evaluation of continuous infusion low-dose 5-azacytidine in the treatment of myelodysplastic syndromes. Am J Hematol 37:100-104
27. Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, Stone RM, Nelson D, Powell BL, DeCastro CM, Ellerton J, Larson RA, Schiffer CA, Holland JF (2002) Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 20:2429-2440 (Pubitemid 34525728)
28. Silverman LR, McKenzie DR, Peterson BL, Holland JF, Backstrom JT, Beach CL, Larson RA (2006) Cancer and Leukemia Group B: Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 24:3895-3903 (Pubitemid 46630737)
29. Heim S (1992) Cytogenetic fi ndings in primary and secondary MDS. Leuk Res 16:43-46
30. Arber DA, Brunning RD, Orazi A et al (2008) Acute myeloid leukaemaia with myelodysplastic- related changes. In: Swerdlow SH, Campo E, Harris NL et al (eds) WHO classification of tumors of haematopoietic and lympohoid tissues (4th edn). Lyon, International Agency for Research on Cancer
31. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD (1999) World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting- Airlie House, Virginia, November 1997. J Clin Oncol 17:3835-3849
32. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Gattermann N, Germing U, Sanz G, List AF, Gore S, Seymour JF, Dombret H, Backstrom J, Zimmerman L, McKenzie D, Beach CL, Silverman LR (2010) Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 28:562-569
33. Maurillo L, Venditti A, Spagnoli A, Gaidano G, Ferrero D, Oliva E, Lunghi M, D'Arco AM, Levis A, Pastore D, Di Renzo N, Santagostino A, Pavone V, Buccisano F, Musto P (2012) Azacitidine for the treatment of patients with acute myeloid leukemia: Report of 82 patients enrolled in an Italian compassionate program. Cancer 118:1014-1022
34. Al-Ali HK, Jaekel N, Junghanss C, Maschmeyer G, Krahl R, Cross M, Hoppe G, Niederwieser D (2012) Azacitidine in patients with acute myeloid leukemia medically un fi t for or resistant to chemotherapy: a multicenter phase I/II study. Leuk Lymphoma 53:110-117
35. Blum W, Garzon R, Klisovic RB, Schwind S, Walker A, Geyer S, Liu S, Havelange V, Becker H, Schaaf L, Mickle J, Devine H, Kefauver C, Devine SM, Chan KK, Heerema NA, Bloomfield CD, Grever MR, Byrd JC, Villalona-Calero M, Croce CM, Marcucci G (2010) Clinical response and miR-29b predictive signi fi cance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci USA 107:7473-7478
36. Lyons RM, Cosgriff TM, Modi SS, Gersh RH, Hainsworth JD, Cohn AL, McIntyre HJ, Fernando IJ, Backstrom JT, Beach CL (2009) Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. J Clin Oncol 27:1850-1856
37. Prebet T, Sun Z, Ketterling RP, Hicks G, Beach CL, Greenberg PL, Paietta EM, Czader M, Gabrilove J, Erba H, Tallman MS, Gore SD (2010) A 10 day schedule of azacitidine induces more complete cytogenetic remissions than the standard schedule in myelodysplasia and acute myeloid leukemia with myelodysplasia- related changes: results of the E1905 US Leukemia Intergroup Study. Blood 116(21):Abst. 4013
38. Marcucci G, Silverman L, Eller M, Lintz L, Beach CL (2005) Bioavailability of azacitidine subcutaneous versus intravenous in patients with the myelodysplastic syndromes. J Clin Pharmacol 45:597-602 (Pubitemid 40562951)
39. Martin MG, Walgren RA, Procknow E, Uy GL, Stockerl-Goldstein K, Cashen AF, Westervelt P, Abboud CN, Kreisel F, Augustin K, Dipersio JF, Vij R (2009) A phase II study of 5-day intravenous azacitidine in patients with myelodysplastic syndromes. Am J Hematol 84:560-564
40. Uchida T, Ogawa Y, Kobayashi Y, Ishikawa T, Ohashi H, Hata T, Usui N, Taniwaki M, Ohnishi K, Akiyama H, Ozawa K, Ohyashiki K, Okamoto S, Tomita A, Nakao S, Tobinai K, Ogura M, Ando K, Hotta T (2011) Phase I and II study of azacitidine in Japanese patients with myelodysplastic syndromes. Cancer Sci 102:1680-1686
41. Kaminskas E, Farrell AT, Wang YC, Sridhara R, Pazdur R (2005) FDA drug approval summary: azacitidine (5-azacytidine, Vidaza) for injectable suspension. Oncologist 10:176-182 (Pubitemid 40463154)
42. Ziemba A, Hayes E, Freeman BB III, Ye T, Pizzorno G (2011) Development of an oral form of azacytidine: 2'3'5'triacetyl-5-azacytidine. Chemother Res Pract 2011:965826
43. Garcia-Manero G, Stoltz ML, Ward MR, Kantarjian H, Sharma S (2008) A pilot pharmacokinetic study of oral azacitidine. Leukemia 22:1680-1684
44. Garcia-Manero G, Gore SD, Cogle C, Ward R, Shi T, Macbeth KJ, Laille E, Giordano H, Sakoian S, Jabbour E, Kantarjian H, Skikne B (2011) Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. J Clin Oncol 29:2521-2527
45. Hollenbach PW, Nguyen AN, Brady H, Williams M, Ning Y, Richard N, Krushel L, Aukerman SL, Heise C, MacBeth KJ (2010) A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. PLoS One 5:e9001
46. Pinto A, Attadia V, Fusco A, Ferrara F, Spada OA, Di Fiore PP (1984) 5-Aza-2′ -deoxycytidine induces terminal differentiation of leukemic blasts from patients with acute myeloid leukemias. Blood 64:922-929
47. Petti MC, Mandelli F, Zagonel V, De Gregoris C, Merola MC, Latagliata R, Gattei V, Fazi P, Monfardini S, Pinto A (1993) Pilot study of 5-aza-2′ -deoxycytidine (Decitabine) in the treatment of poor prognosis acute myelogenous leukemia patients: preliminary results. Leukemia 7(Suppl 1):36-41 (Pubitemid 23184798)
48. Zagonel V, Lo Re G, Marotta G, Babare R, Sardeo G, Gattei V, De Angelis V, Monfardini S, Pinto A (1993) 5-Aza-2′ -deoxycytidine (Decitabine) induces trilineage response in unfavourable myelodysplastic syndromes. Leukemia 7(Suppl 1):30-35 (Pubitemid 23184797)
49. Willemze R, Archimbaud E, Muus P (1993) Preliminary results with 5-aza-2′ -deoxycytidine (DAC)-containing chemotherapy in patients with relapsed or refractory acute leukemia. The EORTC Leukemia Cooperative Group. Leukemia 7(Suppl 1):49-50 (Pubitemid 23184800)
50. Kantarjian HM, O'Brien SM, Estey E, Giralt S, Beran M, Rios MB, Keating M, de Vos D, Talpaz M (1997) Decitabine studies in chronic and acute myelogenous leukemia. Leukemia 11(Suppl 1):S35-S36
51. Wijermans PW, Krulder JW, Huijgens PC, Neve P (1997) Continuous infusion of low-dose 5-Aza-2′ -deoxycytidine in elderly patients with high-risk myelodysplastic syndrome. Leukemia 11(Suppl 1):S19-S23 (Pubitemid 27197354)
52. Wijermans P, Lubbert M, Verhoef G, Bosly A, Ravoet C, Andre M, Ferrant A (2000) Lowdose 5-aza-2′ -deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol 18:956-962 (Pubitemid 30123770)
53. Lubbert M, Wijermans P, Kunzmann R, Verhoef G, Bosly A, Ravoet C, Andre M, Ferrant A (2001) Cytogenetic responses in high-risk myelodysplastic syndrome following low-dose treatment with the DNA methylation inhibitor 5-aza-2′ -deoxycytidine. Br J Haematol 114:349-357 (Pubitemid 32762234)
54. Issa JP, Garcia-Manero G, Giles FJ, Mannari R, Thomas D, Faderl S, Bayar E, Lyons J, Rosenfeld CS, Cortes J, Kantarjian HM (2004) Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′ -deoxycytidine (decitabine) in hematopoietic malignancies. Blood 103:1635-1640 (Pubitemid 38268953)
55. Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J, Faderl S, Bueso- Ramos C, Ravandi F, Estrov Z, Ferrajoli A, Wierda W, Shan J, Davis J, Giles F, Saba HI, Issa JP (2007) Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 109:52-57 (Pubitemid 46053042)
56. Steensma DP, Baer MR, Slack JL, Buckstein R, Godley LA, Garcia-Manero G, Albitar M, Larsen JS, Arora S, Cullen MT, Kantarjian H (2009) Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial. J Clin Oncol 27:3842-3848
57. Blum W, Klisovic RB, Hackanson B, Liu Z, Liu S, Devine H, Vukosavljevic T, Huynh L, Lozanski G, Kefauver C, Plass C, Devine SM, Heerema NA, Murgo A, Chan KK, Grever MR, Byrd JC, Marcucci G (2007) Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. J Clin Oncol 25:3884-3891 (Pubitemid 47477265)
58. Braun T, Itzykson R, Renneville A, de Renzis B, Dreyfus F, Laribi K, Bouabdallah K, Vey N, Toma A, Recher C, Royer B, Joly B, Vekhoff A, Lafon I, Sanhes L, Meurice G, Orear C, Preudhomme C, Gardin C, Ades L, Fontenay M, Fenaux P, Droin N, Solary E (2011) Groupe Francophone des Myelodysplasies: Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial. Blood 118:3824-3831
59. Wijermans PW, Ruter B, Baer MR, Slack JL, Saba HI, Lubbert M (2008) Ef fi cacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML). Leuk Res 32:587-591 (Pubitemid 351248959)
60. Costa R, Abdulhaq H, Haq B, Shadduck RK, Latsko J, Zenati M, Atem FD, Rossetti JM, Sahovic EA, Lister J (2011) Activity of azacitidine in chronic myelomonocytic leukemia. Cancer 117:2690-2696
61. Prebet T, Gore SD, Esterni B, Gardin C, Itzykson R, Thepot S, Dreyfus F, Rauzy OB, Recher C, Ades L, Quesnel B, Beach CL, Fenaux P, Vey N (2011) Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol 29:3322-3327
62. Jabbour E, Garcia-Manero G, Batty N, Shan J, O'Brien S, Cortes J, Ravandi F, Issa JP, Kantarjian H (2010) Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy. Cancer 116:3830-3834
63. Talbert PB, Henikoff S (2010) Histone variants-ancient wrap artists of the epigenome. Nat Rev Mol Cell Biol 11:264-275
64. Lin RJ, Nagy L, Inoue S, Shao W, Miller WH Jr (1998) Evans RM: Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 391:811-814 (Pubitemid 28099682)
65. Altucci L, Gronemeyer H (2001) The promise of retinoids to fi ght against cancer. Nat Rev Cancer 1:181-193 (Pubitemid 33741893)
66. Gelmetti V, Zhang J, Fanelli M, Minucci S, Pelicci PG, Lazar MA (1998) Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO. Mol Cell Biol 18:7185-7191 (Pubitemid 28533038)
67. Richon VM, Emiliani S, Verdin E, Webb Y, Breslow R, Rifkind RA, Marks PA (1998) A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. 95:3003-3007
68. Quintas-Cardama A, Santos FP, Garcia-Manero G (2011) Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia. Leukemia 25:226-235
69. Cameron EE, Bachman KE, Myohanen S, Herman JG, Baylin SB (1999) Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 21:103-107 (Pubitemid 29036293)
70. Gore SD, Baylin S, Sugar E, Carraway H, Miller CB, Carducci M, Grever M, Galm O, Dauses T, Karp JE, Rudek MA, Zhao M, Smith BD, Manning J, Jiemjit A, Dover G, Mays A, Zwiebel J, Murgo A, Weng LJ, Herman JG (2006) Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res 66:6361-6369
71. Fandy TE, Herman JG, Kerns P, Jiemjit A, Sugar EA, Choi SH, Yang AS, Aucott T, Dauses T, Odchimar-Reissig R, Licht J, McConnell MJ, Nasrallah C, Kim MK, Zhang W, Sun Y, Murgo A, Espinoza-Delgado I, Oteiza K, Owoeye I, Silverman LR, Gore SD, Carraway HE (2009) Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood 114:2764-2773
72. Maslak P, Chanel S, Camacho LH, Soignet S, Pandol fi PP, Guernah I, Warrell R, Nimer S (2006) Pilot study of combination transcriptional modulation therapy with sodium phenylbutyrate and 5-azacytidine in patients with acute myeloid leukemia or myelodysplastic syndrome. Leukemia 20:212-217 (Pubitemid 43148657)
73. Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, Yang H, Rosner G, Verstovsek S, Rytting M, Wierda WG, Ravandi F, Koller C, Xiao L, Faderl S, Estrov Z, Cortes J, O'brien S, Estey E, Bueso-Ramos C, Fiorentino J, Jabbour E, Issa JP (2006) Phase 1/2 study of the combination of 5-aza-2′ -deoxycytidine with valproic acid in patients with leukemia. Blood 108:3271-3279
74. Silverman LR, Verma A, Odchimar-Reissig R, LeBlanc A, Nejfeld V, Gabrilove JL (2008) A phase I trial of the epigenetic modulators vorinostat, in combination with azacitidine (azaC) in patients with the myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): a study of the New York Cancer Consortium. Blood 112:3656
75. Garcia-Manero G, Estey E, Jabbour E, Kadia TM, Estrov Z, Cortes J (2010) Phase II study of 5-azacitidine and vorinostat in patients (pts) with newly diagnosed myelodysplastic syndrome (MDS) or acute myelogenous leukemia (AML) not eligible for clinicalt trials because poor performance of presence of other comorbidities. Blood 116:Abstr. 604
76. Garcia-Manero G, Yang AS, Giles F, Faderl S, Ravandi F, Cortes J, Newsome WJ, Issa JP, Patterson TA, Dubay M, Li Z, Kantarjian H, Martell RE (2007) Phase I/II study of MGCD0103, an oral isotype-selective histone deacetylase (HDAC) inhibitor, in combination with 5-Azacitidine in higher-risk myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML). Blood 110
77. Grant S (2009) New agents for AML and MDS. Best Pract Res Clin Haematol 22:501-507
78. Carraway HE, Sidney Kimmel Comprehensive Cancer Center (2000-2012, Feb 11) A trial to evaluate two schedules of MS275 in combination with 5AC in elderly patients with acute myeloid leukemia (AML). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Available from: http://www.clinicaltrials.gov/ct2/show/ NCT01305499:NCT01305499
79. Scandura JM, Roboz GJ, Moh M, Morawa E, Brenet F, Bose JR, Villegas L, Gergis US, Mayer SA, Ippoliti CM, Curcio TJ, Ritchie EK, Feldman EJ (2011) Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML. Blood 118:1472-1480
80. De Padua SL, de Lima M, Kantarjian H, Faderl S, Kebriaei P, Giralt S, Davisson J, Garcia- Manero G, Champlin R, Issa JP, Ravandi F (2009) Feasibility of allo-SCT after hypomethylating therapy with decitabine for myelodysplastic syndrome. Bone Marrow Transplant 43:839-843
81. Lubbert M, Bertz H, Ruter B, Marks R, Claus R, Wasch R, Finke J (2009) Non-intensive treatment with low-dose 5-aza-2′ -deoxycytidine (DAC) prior to allogeneic blood SCT of older MDS/AML patients. Bone Marrow Transplant 44:585-588
82. Field T, Perkins J, Huang Y, Kharfan-Dabaja MA, Alsina M, Ayala E, Fernandez HF, Janssen W, Lancet J, Perez L, Sullivan D, List A, Anasetti C (2010) 5-Azacitidine for myelodysplasia before allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 45:255-260
83. Gerds AT, Gooley TA, Estey EH, Appelbaum FR, Deeg HJ, Scott BL (2012) Pre-transplant therapy with azacitidine vs induction chemotherapy and posttransplant outcome in patients with MDS. Biol Blood Marrow Transplant; in press. [Epub ahead of print]
84. Lubbert M, Bertz H, Wasch R, Marks R, Ruter B, Claus R, Finke J (2010) Ef fi cacy of a 3-day, low-dose treatment with 5-azacytidine followed by donor lymphocyte infusions in older patients with acute myeloid leukemia or chronic myelomonocytic leukemia relapsed after allografting. Bone Marrow Transplant 45:627-632
85. Czibere A, Bruns I, Kroger N, Platzbecker U, Lind J, Zohren F, Fenk R, Germing U, Schroder T, Graf T, Haas R, Kobbe G (2010) 5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis. Bone Marrow Transplant 45:872-876
86. Bolanos-Meade J, Smith BD, Gore SD, McDevitt MA, Luznik L, Fuchs EJ, Jones RJ (2011) 5-Azacytidine as Salvage Treatment in Relapsed Myeloid Tumors After Allogeneic Bone Marrow Transplantation. Biol Blood Marrow Transplant 17:754-758
87. Loh Y (2000) Singapore General Hospital: Study of decitabine induction prior to allogeneic hematopoietic cell transplant in newly diagnosed MDS patients [cited 2012, Feb 11]. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). http:// www.clinicaltrials.gov/ct2/show/ NCT01333449:NCT01333449
88. Shen L, Kantarjian H, Guo Y, Lin E, Shan J, Huang X, Berry D, Ahmed S, Zhu W, Pierce S, Kondo Y, Oki Y, Jelinek J, Saba H, Estey E, Issa JP (2010) DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol 28:605-613
89. Karpf AR, Lasek AW, Ririe TO, Hanks AN, Grossman D, Jones DA (2004) Limited gene activation in tumor and normal epithelial cells treated with the DNA methyltransferase inhibitor 5-aza-2′ -deoxycytidine. Mol Pharmacol 65:18-27 (Pubitemid 38113882)
90. Link PA, Baer MR, James SR, Jones DA, Karpf AR (2008) p53-inducible ribonucleotide reductase (p53R2/RRM2B) is a DNA hypomethylation-independent decitabine gene target that correlates with clinical response in myelodysplastic syndrome/acute myelogenous leukemia. Cancer Res 68:9358-9366
91. Langemeijer SM, Kuiper RP, Berends M, Knops R, Aslanyan MG, Massop M, Stevens- Linders E, van Hoogen P, van Kessel AG, Raymakers RA, Kamping EJ, Verhoef GE, Verburgh E, Hagemeijer A, Vandenberghe P, de Witte T, van der Reijden BA, Jansen JH (2009) Acquired mutations in TET2 are common in myelodysplastic syndromes. Nat Genet 41:838-842
92. Kosmider O, Gelsi-Boyer V, Cheok M, Grabar S, Della-Valle V, Picard F, Viguié F, Quesnel B, Beyne-Rauzy O, Solary E, Vey N, Hunault-Berger M, Fenaux P, Mansat-De Mas V, Delabesse E, Guardiola P, Lacombe C, Vainchenker W, Preudhomme C, Dreyfus F, Bernard OA, Birnbaum D, Fontenay M, Groupe Francophone des Myélodysplasies (2009) TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood 114:3285-3291
93. Itzykson R, Kosmider O, Cluzeau T, Mansat-De Mas V, Dreyfus F, Beyne-Rauzy O, Quesnel B, Vey N, Gelsi-Boyer V, Raynaud S, Preudhomme C, Adès L, Fenaux P, Fontenay M, Groupe Francophone des Myelodysplasies (GFM) (2011) Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia 25:1147-1152
94. Walter MJ, Ding L, Shen D, Shao J, Grillot M, McLellan M, Fulton R, Schmidt H, Kalicki- Veizer J, O'Laughlin M, Kandoth C, Baty J, Westervelt P, DiPersio JF, Mardis ER, Wilson RK, Ley TJ, Graubert TA (2011) Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia 25:1153-1158
95. Ley TJ, Ding L, Walter MJ, McLellan MD, Lamprecht T, Larson DE, Kandoth C, Payton JE, Baty J, Welch J, Harris CC, Lichti CF, Townsend RR, Fulton RS, Dooling DJ, Koboldt DC, Schmidt H, Zhang Q, Osborne JR, Lin L, O'Laughlin M, McMichael JF, Delehaunty KD, McGrath SD, Fulton LA, Magrini VJ, Vickery TL, Hundal J, Cook LL, Conyers JJ, Swift GW, Reed JP, Alldredge PA, Wylie T, Walker J, Kalicki J, Watson MA, Heath S, Shannon WD, Varghese N, Nagarajan R, Westervelt P, Tomasson MH, Link DC, Graubert TA, DiPersio JF, Mardis ER, Wilson RK (2010) DNMT3A mutations in acute myeloid leukemia. N Engl J Med 363:2424-2433
96. Thol F, Damm F, Lüdeking A, Winschel C, Wagner K, Morgan M, Yun H, Göhring G, Schlegelberger B, Hoelzer D, Lübbert M, Kanz L, Fiedler W, Kirchner H, Heil G, Krauter J, Ganser A, Heuser M (2011) Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. J Clin Oncol 29:2889-2896